



September 04, 2009 03:46 PM Eastern Daylight Time 

AxoGen Announces U.S. Market Launch of AxoGuard™ Nerve Protector and AxoGuard™ Nerve Connector to Treat Peripheral Nerves

AxoGuard™ Expands AxoGen Portfolio of Nerve Repair Products

SAN FRANCISCO--([BUSINESS WIRE](#))--AxoGen, Inc. today announced the U.S. market launch of AxoGuard™ Nerve Protector and AxoGuard™ Nerve Connector for the treatment of peripheral nerve injuries. The launch was announced at the American Society for Surgery of the Hand in San Francisco.

AxoGuard™ Nerve Protector is designed to wrap and protect peripheral nerves. It can reinforce a coaptation site, wrap a partially severed or compressed nerve, and isolate nerve tissue during the healing process. The design minimizes the potential for scar formation and nerve entrapment while reducing the risk of neuromas. It allows the nerve to glide within a protective covering while gradually remodeling into the patient's own tissue.

AxoGuard™ Nerve Connector is designed to align and connect peripheral nerves. It is a coaptation aid, meaning it joins together two nerve endings, allowing close approximation and alignment of severed nerve ends.

"We are very pleased to add AxoGuard™ Nerve Protector and AxoGuard™ Nerve Connector to our portfolio of peripheral nerve repair products," said Jamie Grooms, CEO and Co-founder of AxoGen. "With these products and our national sales and marketing support network, AxoGen is more than ever a resource and partner with surgeons working to treat the peripheral nerve injuries that affect thousands of patients each year."

AxoGuard™ Nerve Protector and AxoGuard™ Nerve Connector are comprised of a three-dimensional extracellular matrix that supports regeneration and healing. AxoGuard™ works with the body to remodel and revascularize, allowing the products to support the natural nerve healing process. In addition, AxoGuard™, unlike other materials such as synthetics, is able to be implanted into a contaminated or dirty wound, since the material is resistant to infection.

AxoGuard™ is available nationally and will be sold through the AxoGen sales network. AxoGen also distributes Avance®, the first decellularized and cleansed, sterile three-dimensional scaffold from donated human peripheral nerve. Avance® is designed to bridge peripheral nerve gaps. It structurally supports the patient's own regeneration process to repair the nerve.

About AxoGen

AxoGen, Inc. is a privately held company working to develop new and more effective products to treat peripheral nerve damage. With the focus of bringing the science of nerve repair to life, AxoGen is working to introduce new technologies to improve the standard of care for patients with injured peripheral nerves. With licensed technologies from the University of Florida, the University of Texas, and Emory University, researchers at AxoGen have developed an innovative technology platform making it possible to process allograft nerves while preserving the three dimensional scaffold and key components of the tissue. Based in Alachua, Florida, AxoGen has received funding from private investors including Accuitive Medical Ventures, Cardinal Partners, De Novo Ventures, Springboard Capital II, LLC, SynoGen, and Emergent Growth Fund of Gainesville, FL.

AxoGen is a registered tissue bank with the FDA.

AxoGuard™ is manufactured by Cook Biotech, Inc.

Contacts

AxoGen, Inc.

Monica L. Tarver, 386-462-6834

mtarver@axogeninc.com

Permalink: <http://www.businesswire.com/news/home/20090904005523/en>

